Literature DB >> 18706893

Phosphodiesterase 3 and 4 comprise the major cAMP metabolizing enzymes responsible for insulin secretion in INS-1 (832/13) cells and rat islets.

Deena Waddleton1, Weizhen Wu, Yue Feng, Chris Thompson, Michael Wu, Yun-Ping Zhou, Andrew Howard, Nancy Thornberry, Jing Li, Joseph A Mancini.   

Abstract

cAMP is a key modulator for glucose-dependent insulin secretion (GDIS). Members of the phosphodiesterase (PDEs) gene family regulate intracellular levels of cAMP by hydrolyzing cAMP to the corresponding inactive 5'AMP derivative. These studies examined the expression and function of all 18 cAMP-specific PDEs in the rat insulinoma derived INS-1 (832/13) cell and isolated rat islets using quantitative PCR and siRNA-mediated gene-specific knockdown. PDE1C, PDE3B, PDE4C, PDE8B, PDE10A, and PDE11A were significantly expressed in rat islets and INS-1 (832/13) cells at the mRNA level. PDE1C, PDE10A and PDE11A were also expressed in brain, along with PDE3B, PDE4C and PDE8B which were also highly expressed in liver, and PDE3B was present in adipose tissue and PDE4C in skeletal muscle. siRNA mediated knockdown of PDE1C, PDE3B, PDE8B and PDE4C, but not PDE10A and PDE11A, significantly enhanced GDIS in rat INS-1 (832/13) cells. Also, selective inhibitors of PDE3 (trequinsin) and PDE4 (roflumilast and L-826,141) significantly augmented GDIS in both INS-1 (832/13) cells and rat islets. The combination of PDE3 and PDE4 selective inhibitors demonstrate that these enzymes comprise a significant proportion of the cAMP metabolizing activity in INS-1 cells and rat islets.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18706893     DOI: 10.1016/j.bcp.2008.07.025

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  27 in total

1.  Monomethylated-adenines potentiate glucose-induced insulin production and secretion via inhibition of phosphodiesterase activity in rat pancreatic islets.

Authors:  Brandon B Boland; Cristina Alarcón; Almas Ali; Christopher J Rhodes
Journal:  Islets       Date:  2015-09-24       Impact factor: 2.694

2.  Adenylyl cyclase 8 is central to glucagon-like peptide 1 signalling and effects of chronically elevated glucose in rat and human pancreatic beta cells.

Authors:  B Roger; J Papin; P Vacher; M Raoux; A Mulot; M Dubois; J Kerr-Conte; B H Voy; F Pattou; G Charpentier; J-C Jonas; N Moustaïd-Moussa; J Lang
Journal:  Diabetologia       Date:  2010-11-03       Impact factor: 10.122

3.  Calpain inhibitor and ibudilast rescue β cell functions in a cellular model of Wolfram syndrome.

Authors:  Lien D Nguyen; Tom T Fischer; Damien Abreu; Alfredo Arroyo; Fumihiko Urano; Barbara E Ehrlich
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-06       Impact factor: 11.205

Review 4.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

5.  Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.

Authors:  Nicola J Sinden; Robert A Stockley
Journal:  Ther Adv Chronic Dis       Date:  2010-03       Impact factor: 5.091

6.  Expression and regulation of cyclic nucleotide phosphodiesterases in human and rat pancreatic islets.

Authors:  Emilia Heimann; Helena A Jones; Svante Resjö; Vincent C Manganiello; Lena Stenson; Eva Degerman
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

Review 7.  Resveratrol as a calorie restriction mimetic: therapeutic implications.

Authors:  Jay H Chung; Vincent Manganiello; Jason R B Dyck
Journal:  Trends Cell Biol       Date:  2012-08-10       Impact factor: 20.808

8.  Induction of miR-132 and miR-212 Expression by Glucagon-Like Peptide 1 (GLP-1) in Rodent and Human Pancreatic β-Cells.

Authors:  Jin Shang; Jing Li; Mark P Keller; Hans E Hohmeier; Yong Wang; Yue Feng; Heather H Zhou; Xiaolan Shen; Mary Rabaglia; Mufaddal Soni; Alan D Attie; Christopher B Newgard; Nancy A Thornberry; Andrew D Howard; Yun-Ping Zhou
Journal:  Mol Endocrinol       Date:  2015-07-28

9.  Repurposing cAMP-modulating medications to promote β-cell replication.

Authors:  Zhenshan Zhao; Yen S Low; Neali A Armstrong; Jennifer Hyoje Ryu; Sara A Sun; Anthony C Arvanites; Jennifer Hollister-Lock; Nigam H Shah; Gordon C Weir; Justin P Annes
Journal:  Mol Endocrinol       Date:  2014-08-01

10.  The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice.

Authors:  S Vollert; N Kaessner; A Heuser; G Hanauer; A Dieckmann; D Knaack; H P Kley; R Beume; C Weiss-Haljiti
Journal:  Diabetologia       Date:  2012-07-13       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.